Catherine M. Broome - Concepedia

Author

Catherine M. Broome

Georgetown University ORCID

Also Known As

C. Broome, C. M. BROOME, C. M. Broome, C.M. Broome, Catherine Broome, Catherine M Broome, Catherine M. Broome

125

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Georgetown University MedStar Georgetown University Hospital Massachusetts General Hospital University of Duisburg-Essen University College London

About

Catherine M. Broome is an author at Georgetown University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	9	581
2	Health Sciences	5	6	351
3	Allergy	3	3	175
4	Clinical Immunology	1	1	23
5	Hepatology	1	1	14

Catherine M. Broome

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Sutimlimab in Cold Agglutinin Disease Alexander Röth, Wilma Barcellini, Shirley D’Sa, New England Journal of Medicine	2021	198
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer David J. Vaughn, Catherine M. Broome, Maha Hussain, Journal of Clinical Oncology UrologyOncologyPhase Ii TrialGenitourinary CancerUrothelial Cancer	2002	193
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Blood ImmunohematologyCadenza TrialImmunodeficienciesImmunologyImmunotherapy	2022	103
Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer Howard A. Burris, Denise A. Yardley, Suzanne F. Jones, Journal of Clinical Oncology	2004	99
Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis Catherine M. Broome, Julia Cunningham, Megan A. Mullins, Research and Practice in Thrombosis and Haemostasis	2020	82
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, The Lancet ThrombopoiesisAutoimmune DiseaseBlood PlateletPrimary Immune ThrombocytopeniaImmunology	2023	77
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia Catherine M. Broome, Alexander Röth, David J. Kuter, Blood Advances ImmunohematologyImmunodeficienciesImmunologyPathologyImmunotherapy	2022	52
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study David J. Kuter, Kerry A. Rogers, Michael Boxer, American Journal of Hematology	2022	34
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results Alexander Röth, Wilma Barcellini, Shirley D’Sa, Haematologica Clinical ImmunologyInflammationComplement SystemLaboratory ImmunologyPathogenesis	2022	23
<scp>Freeze‐dried</scp> platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies Maro Ohanian, José A. Cancelas, Robertson D. Davenport, American Journal of Hematology ImmunohematologyWorld Health OrganizationShelf LifeImmunologyPlatelet Pathobiology	2021	22

Page 1